uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Psychiatry, University Hospital. Centre for pharmacoepidemiology, Karolinska Institutet.
2014 (English)In: International journal of clinical practice (Esher), ISSN 1368-5031, E-ISSN 1742-1241, Vol. 68, no 1, 104-110 p.Article in journal (Refereed) Published
Abstract [en]

AIM: To assess prescribing patterns, sociodemographic characteristics and previous disease history in patients receiving pregabalin.

METHODS: An observational study using register data on dispensed drugs and recorded diagnoses for all patients in Stockholm, Sweden, who filled at least one prescription of pregabalin between July 2005 and December 2009. Analyses focused on prevalence, incidence, diagnosis patterns, prior dispensing of other analgesics/psychotropics and persistence to treatment over time.

RESULT: A total of 18,626 patients (mean age 55 years, 63% women) were initiated on treatment between July 2006 and December 2009. Approved indications were recorded in hospital and/or primary care within 1 year prior to the first dispensing for 40% of the patients (epilepsy 1.3%, neuropathic pain 35.5% and generalised anxiety disorder (GAD) 3.6%). Antidepressants were used by 55%, opioids by 49% and sedatives by 48% prior to initiation of pregabalin. One-third (34%) only purchased one prescription and the proportion purchasing pregabalin 1 year after initiation was 42.1% for epilepsy, 36.3% for GAD, 21.5% for neuropathic pain and 25.6% for those without any of the included diagnoses.

CONCLUSION: Pregabalin was mainly used as a second-line drug for the treatment of GAD or neuropathic pain and to a lesser extent as add-on therapy in epilepsy. However, a large proportion of all patients only purchased one prescription and the persistence declined rapidly over time. The issue of potential off-label prescribing or poor registration of diagnoses should also be noted as a high proportion had been prescribed the drug without a record of any of the approved indications.

Place, publisher, year, edition, pages
2014. Vol. 68, no 1, 104-110 p.
National Category
Psychiatry Neurology Pharmaceutical Sciences Public Health, Global Health, Social Medicine and Epidemiology
URN: urn:nbn:se:uu:diva-209411DOI: 10.1111/ijcp.12182ISI: 000328375000013PubMedID: 23815622OAI: oai:DiVA.org:uu-209411DiVA: diva2:657294
Available from: 2013-10-18 Created: 2013-10-18 Last updated: 2014-01-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Bodén, Robert
By organisation
Psychiatry, University Hospital
In the same journal
International journal of clinical practice (Esher)
PsychiatryNeurologyPharmaceutical SciencesPublic Health, Global Health, Social Medicine and Epidemiology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 279 hits
ReferencesLink to record
Permanent link

Direct link